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The cholesterol-reducing drug atorvastatin is widely used in hyperlipidemic patients and it
is crucial to consider its potential myotoxic effect when adjusting the prescription for
patients. The aim of this study was to establish a simple high-performance liquid chro-
matography method that would be applicable for the quantitative determination of high
serum atorvastatin concentrations in patients for the assessment of myalgia. The average
recovery of atorvastatin from the extraction using ethyl acetate was 85.1%. The extract was
dried, re-dissolved in methanol, and subjected to chromatographic separation using a
reverse-phase C18 analytical column and a mobile phase consisting of 61.3% methanol in
0.05 M sodium phosphate buffer at pH 3.5. The concentration of atorvastatin was quanti-
tatively determined by measuring the absorbance at 247 nm and b-naphthoflavone was
used as an internal standard. The lower limits of detection and quantification of atorvas-
tatin were 1.2 ng/mL and 3.0 ng/mL, respectively. There was a good linear relationship
(r ¼ 0.999) of the peak area and atorvastatin within a concentration range of 3.0e150 ng/mL
in human serum. Among 61 lipid-controlling patients with detectable serum atorvastatin
concentrations, 7 patients had myalgia and their serum concentrations were not signifi-
cantly greater than those in patients without myalgia.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license.1. Introduction biosynthesis. Atorvastatin accounted for the second highestStatins are considered to be the most effective drugs for
the treatment of hyperlipidemia. Atorvastatin belongs to
the group of statins and is a potent competitive inhibitor of
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reduc-
tase, which is the rate-limiting enzyme in cholesterolnstitute of Chinese Medic
. Ueng).
ministration, Taiwan. Publdrug expense of the National Health Insurance in Taiwan
(Annual Report of the Bureau of National Health Insurance
2011, Department of Health, Executive Yuan, Taiwan).
Compared to other statins, atorvastatin has a relatively low
clearance (0.25 L/h/kg) and its half life is longer (15e30 hours)
[1]. The absorption andoral bioavailability of atorvastatinwereine, 155-1, Li-Nong Street, Section 2, Taipei 112, Taiwan, ROC.
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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muscleswith creatine kinase (CK) 10 times the upper limit of
normal (ULN) range] is the primary cause of statin intolerance,
and the development of myopathy has been suggested to be
affected by factors resulting in an increase in the blood con-
centration of statins [2]. However, the induction of myopathy
by statins is not common (about 0.1e2.5%). Compared to
myopathy, myalgia (sore and weak muscles with normal CK
levels) is a milder syndrome and occurs more frequently
(5e10%) [3]. Among statins, a meta-analysis of myalgia in a
total of 48,138 patients in 21 studies showed that only ator-
vastatin elicited a significantly higher risk of myalgia than
placebo [4]. It has been suggested that the incidence of myop-
athy increased in patients taking a high dosage (80 mg/d) of
simvastatin [5]. Other potential risk factors of statin-induced
myopathy include age, sex, drug interaction and polymorphic
expression of cytochrome P450s and transporters [1,4e7]. Ac-
cording to thehighermyopathy/myalgia risk in thehighstatin-
dosinggroup [3,5] and that blood statin (including atorvastatin)
concentration or pharmacokinetic parameters could be
changed through drug interactions [7e9] and polymorphic
expression of drug-metabolizing enzyme/transporters
[1,4,6,10], it could be important to monitor the high blood
concentrations of atorvastatin in patients for the assessment
of myalgia risk. However, there are few reports showing the
difference in blood atorvastatin concentrations between pa-
tients with and without myalgia syndrome.
Although gas chromatography/mass spectrometry (GC/MS)
and liquid chromatography/mass spectrometry (LC/MS)
provide methods with high detection sensitivities for the
determination of atorvastatin [2,11], the high cost of these in-
struments, instrument maintenance and sample preparation
as well as the limited uses are problems in many research
laboratories. Bahrami et al [12] reported a simple and fast
high-performance liquid chromatography (HPLC) method
using diclofenac as an internal standard and a column
oven temperature of 62C. This method was suggested to be
applicable for the determination of the bioequivalence of
different atorvastatin preparations in healthy participants.
However, diclofenac is currently used as an analgesic, which
may be taken together with atorvastatin in hyperlipidemic
patients. There is difficulty in the application of thismethod to
monitor atorvastatin concentrations in patients undergoing
multidrug treatment. In this report, we describe a HPLC
method using a non-therapeutic agent, b-naphthoflavone, as
an internal standard for the quantitative analysis of atorvas-
tatin in blood samples of lipid-controlling patients. This HPLC
analysiswas carriedout at roomtemperatureand therewasno
need for a column oven. Serum atorvastatin concentrations
were determined in 69 Taiwanese patients and 7 of them had
myalgia.2. Methods
2.1. Chemicals
The calcium salt of atorvastatin was purchased from the U.S.
Pharmacopeial Convention (USP, Boston, MA, USA). Methanol
and ethyl acetate were purchased fromMerck Co. (Darmstadt,Germany). Sodium dihydrogen phosphate, disodium
hydrogen phosphate, sodium hydroxide and o-phosphoric
acid were purchased from JT Baker (Mallinckrodt Baker, Inc.,
Phillipsburg, NJ, USA). Acetaminophen, diclofenac, a-naph-
thoflavone, b-naphthoflavone, theophylline and verapamil
were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).
2.2. Participants and serum preparation
Studies involving the handling of human blood samples were
approved by the institutional review board of Taipei Veterans
General Hospital, Taiwan (VGHIRB no.: 201003009IA). A total of
69 patients with a mean  standard deviation (SD) age of
60.1 12.7 years (range, 19e86years), takingaQDdoseof 10mg
(32 patients) or 40mg atorvastatin (37 patients) formore than 3
monthswere included.Beforebloodcollection, thepatientsdid
not drinkgrapefruit juice for at least 2weeks.Neither inducers/
inhibitors of cytochrome P450 3A4 nor inhibitors of organic
anion transport protein 1B1was taken by the participants. The
meanSD low-density lipoprotein cholesterol andCK levels of
the 69 patients were 97.5  23.8 mg/dL (range, 40e173 mg/dL)
and 97.3  90.5 U/L (range, 29e207 U/L), respectively. In this
study, none of the patients had aCK level greater than 10 times
the ULN (the normal range of CK is 27e168 U/L in males and
24e120 U/L in females). Three of the 10 mg-dosing group and
four of the 40mg-dosing grouphadmyalgiawith complaints of
muscle pain/soreness or weakness. Among the participants,
seven had CK levels greater than the ULN and only one female
patient (40mg-dosing) hadmuscle pain/soreness. Her CK level
was 148 U/L, whereas the other patients with myalgia had CK
levels within the normal range. Blood samples were collected
from participants after overnight fasting at their regular
(monthly) hospital visits between 9:00 AM and 12:00 PM. Sera
were prepared by centrifugation of blood samples at 1800g for
10 minutes at 4C. After centrifugation, the supernatant
(serum) was collected and stored at 75C until analysis. Dur-
ing the handling of human samples, protective clothes and
gloves were put on. The waste left from handling human
samples was disinfected by autoclave.
2.3. Extraction and chromatography
Atorvastatin and b-naphthoflavone (internal standard) solu-
tions were prepared using methanol and stored at e20C.
Stock solutions (1 mg/mL atorvastatin and 1 mg/mL b-naph-
thoflavone) were stable for at least 4 weeks. To a 1-mL aliquot
of human serum samples, 200 ng of b-naphthoflavone was
added. An equal volume of 0.1 M sodiumphosphate buffer (pH
7.0) was added, mixed and subjected to extraction by 5 mL of
ethyl acetate [6]. After mixing by vortex for 30 seconds, the
samples were centrifuged at 1600g for 10 minutes at room
temperature and the organic layer was collected and evapo-
rated to dryness under nitrogen. The residue was re-dissolved
in 80 mL ofmethanol and an aliquot of 60 mL was injected into a
HPLC system (Agilent 1100 series; Agilent Technologies, Santa
Clara, CA, USA) equipped with a degasser, a pump and a
photodiode array detector (G1315B). Chromatographic sepa-
ration was performed using a C18 analytical column
(150 mm  4.6 mm I.D., 5 mm) (Ascentis; Sigma-Aldrich) and a
mobile phase of 10% methanol in 0.05 M sodium phosphate
Table 1 e Retention times of candidates for internal
controls.
Chemical Retention time (min)
Acetaminophen 2.1
Diclofenac 18.2
a-Naphthoflavone 41.1
b-Naphthoflavone 56.1
Theophylline 2.2
Verapamil 3.4
Chromatography was carried out as described in the Methods
section.
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anol (43/57, v/v) at a flow rate of 1.2 mL/min. The extraction
efficiencies (recoveries) of atorvastatin were assessed from
triplicate determinations by adding 5, 10 and 50 ng/mL of
atorvastatin to the blank serum and the percentages of the
resulting peak areas compared to the respective peak areas of
pure solutions of the same atorvastatin concentration (in
methanol) were calculated. The concentration of atorvastatin
was quantified by measuring the absorbance at 247 nm, and
the peak area of atorvastatin normalized by the relative peak
area of b-naphthoflavone (mean peak area of b-naphtho-
flavone was defined as 1.0) was used for the calculation of
concentration.
2.4. Calibration curve and method validation
Calibration curves were established by linear regression
analysis of the peak area as a function of atorvastatin con-
centrations in sera spiked with 3, 4, 5, 10, 25, 50, 100 and
150 ng/mL of atorvastatin. The extraction, chromatography
and normalized peak area determination were carried out as
described above. The specificity of the method was evaluated
by the analysis of blank serum samples from five healthy
volunteers. Intra- and inter-day precision and accuracy were
determined by analyzing 5.0e150 ng/mL of atorvastatin ana-
lytes in triplicate on the same day and on 3 different days,
respectively. Determinations were performed using the same
stock solutions and a pooled serum sample from healthy
volunteers. The accuracy was calculated as the percentage of
mean observed concentration compared to the nominal con-
centration. The precision evaluation shown as the relative
standard deviation (RSD) was calculated as the percentage of
standard deviation compared to the observed concentration.
The limit of detection (LOD) for thismethodwas defined as the
concentration of drug giving a signal-to-noise ratio of 3. The
limit of quantification (LOQ) was defined as the lowest con-
centration of atorvastatin in blank serum that could be
quantified with the inter-assay SD of less than 20%.
2.5. Data analyses
The datawere expressed asmean SD. Themedian value and
interquartile range were calculated using SPSS version 17.0
(IBM Corp., New York, NY, USA). The statistical significance in
the difference between serum atorvastatin concentrations in
patients with and without myalgia was evaluated by logistic
regression analysis using SPSS software.3. Results and discussion
To establish a HPLC method for the quantification of ator-
vastatin in patients, we compared the retention time of
several internal standard candidates including acetamino-
phen, diclofenac, a-naphthoflavone, b-naphthoflavone,
theophylline and verapamil for a qualified separation from
atorvastatin (Table 1, Fig. 1A) and background peaks of serum
samples. The chromatogram of human blank serum from
healthy volunteers is shown in Fig. 1B; several absorbance
peaks appear in the chromatogram of the blank serumsample. In the blank serum sample spiked with atorvastatin
and b-naphthoflavone, b-naphthoflavone was clearly sepa-
rated from the endogenous peaks (Figs. 1CeE). No interference
peak appeared at the retention time relevant to atorvastatin
and b-naphthoflavone, indicating a good selectivity of this
method. The retention times of atorvastatin and b-naphtho-
flavone were 19.8 and 56.1 minutes, respectively. However,
compared to b-naphthoflavone, the other candidate chem-
icals did not show better separation from atorvastatin and the
endogenous peaks (Table 1). The spectra (200e400 nm) of
selected peaks with retention time equivalent to atorvastatin
and b-naphthoflavone in the chromatograms of patients’ sera
were comparable to the pure standard solution (data not
shown). Thus, b-naphthoflavone was used as an internal
standard in the chromatographic analysis.
The extraction recoveries of atorvastatin from sera spiked
with 5, 10 and 50 ng/mL of atorvastatin are listed in Table 2.
The mean recovery of sample preparations was 85.1%. The
LOD and LOQ were 1.2 ng/mL and 3.0 ng/mL, respectively.
Using liquideliquid extraction in the blood sample prepara-
tion and HPLC method in the detection of atorvastatin, other
reports had LOD and LOQ values of 1.0e1.9 ng/mL and
3.0e5.6 ng/mL, respectively [12e14]. Our method had detec-
tion sensitivity comparable to these reported methods. In
addition to absorbance measurement, atorvastatin also has
detectable fluorescence [15]. However, the quantification of
blood atorvastatin concentration by measuring its fluores-
cence has not been reported. Amethod using acceptor droplet
directly suspended in liquideliquideliquid microextraction
for sample preparation was reported to decrease the LOD of
the HPLCmethod to 0.4 ng/mL [16]. However, this method has
not been commonly used. In our determinations, atorvastatin
concentrations at 3.0e150 ng/mL had a good linear relation-
ship with the peak area in the chromatograms of blank sera
spiked with atorvastatin (r ¼ 0.999) (Fig. 2). The RSD values of
intra- and inter-day analyses were within a range of 2e17%
(Table 3). The accuracies of intra-day and inter-day analyses
were 92.8e118.7% and 92.2e119.8%, respectively. For the
quantification of atorvastatin, LCeMS/MS analysis provides a
highly sensitive method with a quantification limit as low as
0.25 ng/mL [2]. In studies using this method in healthy vol-
unteers of different ethnicities, the mean Cmax values after
taking a 10e40 mg dose of atorvastatin were 12.7e50.1 ng/mL
(Table 4) [2,7e9,16]. In lipid-controlling Caucasian patients,
the serum atorvastatin concentrations were in the range of
0e30.4 ng/mL, with median values of 5.4e23.7 ng/mL [16].
Although the HPLC method was not as sensitive as the
Fig. 1 e (A) HPLC chromatogram of internal control candidates: 1[ theophylline; 2[ verapamil; 3[ diclofenac; 4[ a-
naphthoflavone; 5[ b-naphthoflavone. (B) Representative HPLC chromatogramof blank human serum sample. Representative
HPLCchromatogramsofblankhumanserumsamplesspikedwithb-naphthoflavone200ng/mLand: (C) atorvastatin3ng/mL; (D)
atorvastatin5ng/mL; (E) atorvastatin50ng/mL; (F) atorvastatin100ng/mL.Peaks1and2 inpanelsCeF indicate theappearanceof
atorvastatin andb-naphthoflavone, respectively. The signal-to-noise ratios for 3, 5, 50 and100ng/mLof atorvastatin in theHPLC
chromatograms were 5.5 ± 0.4, 7.9 ± 0.4, 45.6 ± 2.2 and 102.8 ± 2.2, respectively (mean ± SD of three determinations).
Table 2 e Recoveries of samples prepared from sera
spiked with defined concentrations of atorvastatin.
Atorvastatin
concentration
(ng/mL)
Recovery of
atorvastatin (%)
5 88.5  3.6
10 82.4  1.5
50 84.4  1.6
Data represent the mean  SD of three determinations.
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and the other HPLC methods were lower than the mean Cmax
and median values of atorvastatin concentrations shown in
Table 4. These results indicate that the HPLC method may
provide a lower-cost alternative for the study of the adverse
effects potentially induced by high concentration exposure.
In this study, blood samples were collected during the
outpatients’ regular hospital visit in the morning. The time
period from drug administration to blood sampling could be
different among patients and might have affected the serum
[Atorvastatin], ng/mL
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Fig. 2 e The linear relationship between the peak area
ratios of atorvastatin to b-naphthoflavone and atorvastatin
concentrations in human sera spiked with increasing
concentrations of atorvastatin. Various concentrations
(3e150 ng/mL) of atorvastatin were added to the blank
serum, extracted, dried under nitrogen, and re-dissolved in
methanol as described in the Methods section. The areas of
atorvastatin and b-naphthoflavone peaks in the
chromatogram with absorbance detection at 247 nm were
determined. The results represent the mean ± SD of three
determinations.
Table 4 e Atorvastatin concentrations in human blood.
Human
sample
Oral
dose
(mg)
n Atorvastatin (ng/mL)
Median or
mean  SD
Range Reference
Asian
Chinese 20 18 8.54  5.06
(Cmax)
NA 2
Japanese 10 10 4.6 (Cmax) NA 7
Taiwanese 10 27 9.4  17.1 a n.d.e140.1 Present
study32 3.0 a (median)
40 34 4.1  5.5 a n.d.e42.5 Present
study37 4.3 a (median)
Caucasian
American 10 22 5.4 b
(median)
0e10.2 9
20 17 17.6 b
(median)
9.1e27 9
40 9 23.7 b
(median)
6e30.4 9
Finnish 40 12 12.7  7.8
(Cmax)
NA 8
Iranian 40
(Arya)
12 50.1  30.7
(Cmax)
NA 12
40
(Pfizer)
12 47.0  27.5
(Cmax)
NA 12
Norwegian 10 13 3.1 (Cmax)
(median)
1.3e7.9 17
10 15 2.5 (Cmax)
(median)
1.0e12.8 17
NA 40 NA NA 48e118 18
NA ¼ data not available; n.d. ¼ not determinable (<1.2 ng/mL).
The median values of serum atorvastatin concentrations were
determined in Taiwanese patients, including patients with serum
concentrations below the detection limit, whereas only determin-
able data were included in the calculation of mean  SD.
a In our study, blood samples were collected when atorvastatin-
treated patients visited hospital for their monthly follow-up
health monitoring.
b In the report of Reddy et al [9], patients received atorvastatin for
more than 90 days before the study and the values show the
baseline data of serum atorvastatin concentrations in patients
before taking grapefruit juice.
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tin is 15e30 hours, the difference in serum concentration
caused by variations in the time period after dosing may be
less than 50%. Our determination of serum atorvastatin con-
centrations using the HPLC method showed that the serum
atorvastatin concentrations in Taiwanese patients were
within the concentration ranges for different ethnic groups
(Table 4). Serum atorvastatin concentrations in eight patients
were below the detection limit. The median value and inter-
quartile range of detectable atorvastatin concentrations in the
other 61 patients were 4.3 ng/mL and 4.5 ng/mL, respectively.
The mean  SD serum concentration was 10.8  22.8 ng/mL.
The variations between individuals were high with the SDTable 3 e Precision and accuracy of intra- and inter-day valida
Expected
concentration
(ng/mL)
Intra-day (n ¼ 3)
Observed (ng/mL)
Mean  SD
RSD (%) Accurac
5 5.9  0.9 15.1 118.
10 9.3  0.6 6.6 92.
25 23.3  0.6 2.7 93.
50 50.8  1.2 2.4 101.
100 102.2  4.8 4.7 102.
150 148.8  5.4 3.7 99.
Data represent the mean  SD of three determinations.being greater than the mean value. This HPLC method may
not be ideal for the measurement of low serum concentra-
tions, but concentrations greater or equal to median values
were quantifiable. This method could provide a cheaper, lesstion of quantification of atorvastatin.
Inter-day (n ¼ 3)
y (%) Observed (ng/mL)
Mean  SD
RSD (%) Accuracy (%)
7 6.0  1.0 17.4 119.8
8 11.0  1.2 11.0 110.3
1 23.2  0.9 3.9 92.9
7 46.1  3.4 7.4 92.2
2 105.6  2.1 8.8 105.6
2 148.0  5.3 3.6 98.7
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mass spectral determination for the quantification of high
serum concentration for risk assessment in patients.
Reddy et al [9] reported that the median values of serum
concentrations in 20mg and 40mg atorvastatin-dosing groups
are 226% and 339% higher than that in the 10 mg-dosing group
of patients, respectively (Table 4). Our results showed that the
median value and interquartile range of detectable serum
concentrations in the 10-mg dosing group were 3.5 ng/mL and
8.7 ng/mL, respectively (Fig. 3). The median value and inter-
quartile range of serum atorvastatin concentration in the
40 mg-dosing group were 4.4 ng/mL and 3.6 ng/mL, respec-
tively. Themedian value of serumconcentrations in the 40mg-
dosing group was only 26% higher than that in the 10 mg-
dosing group. This difference is not as much as that reported
by Reddy et al [9]. However, the mean value of serum con-
centration was not higher in the higher dosing group. Factors
including the detection sensitivity of low serum concentration,
outliers and high inter-individual difference could interfere
with the group comparison when the mean value is used.
In the 10 mg-dosing group with myalgia, the median
atorvastatin concentration in patients with and without
myalgia were 11.0 (n ¼ 3, the interquartile range could not be
calculated) and 3.0 (n ¼ 24, with an interquartile range of
6.7 ng/mL), respectively. The median value in the group of
patients with myalgia was 293% greater than in the patients
without myalgia (Fig. 3). However, there was no similar
observation in the 40 mg-dosing group. In the 40 mg-dosing
group, the median values were almost the same in patientsFig. 3 e Serum atorvastatin concentrations in hyperlipidemic p
Among 61 patients with a detectable serum level of atorvastatin
myalgia, while 34 patients took 40 mg of atorvastatin and 4 of
represents the 75th and 25th percentiles, respectively. The line
extending from the box represent the highest and lowest value
asterisks represent the outliers (values that are between 1.5 and
that are more than 3 times the interquartile range), respectivelywith and without myalgia (the difference was less than 5%). A
myalgia study of Caucasians in Norway [17] demonstrated
that the atorvastatin concentrations in lipid-controlling pa-
tients with muscular side effects were not significantly higher
than those in healthy participants taking the same dosing
regimen of atorvastatin. Our study compared patients with
and without myalgia and found no significant difference
either. Logistic regression analysis of serum concentrations in
61 patients showed that there was no significant increase in
serum atorvastatin concentration in patients with myalgia
( p ¼ 0.293). Among the 61 patients, 27 and 34 patients took a
daily dose of 10 mg and 40 mg of atorvastatin, respectively.
The difference in concentrations between patients with and
without myalgia was not significant in both the 10-mg
( p ¼ 0.689) and 40-mg ( p ¼ 0.575) dosing groups.
The more lipophilic lactone form (pharmacologically
inactive) of atorvastatin has been suggested to cause higher
toxicity than the acid form (pharmacologically active) in
skeletal muscle cells [18,19]. Due to the significant difference
between the portion of correctly predicted positive and
negative diagnoses, the ratio of atorvastatin lactone to acid
has been suggested to be helpful in the assessment of statin-
inducedmyopathy [19]. However, the ratio of lactone to acid in
patients with myalgia is not significantly different from the
ratio in patients without myalgia. The cytotoxicity of lactone
metabolite in muscle cells occurs at an exposure concentra-
tion greater than 100 mM, which is much higher than the
plasma Cmax values (w3.6e37.2 nM) of lactone metabolite in
patients and healthy participants taking atorvastatin [10,17].atients with and without myalgia after taking atorvastatin.
, 27 patients took 10 mg of atorvastatin and 3 of them had
them had myalgia. The top and bottom lines of the box
in the middle represents the median value. The whiskers
s that are not outliers or extreme values. Circles and
3 times the interquartile range) and extreme values (values
.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 1 ( 2 0 1 3 ) 1 4 7e1 5 3 153In this study, we did not determine the serum concentration
of atorvastatin lactone. The contributions of lactone metabo-
lite to statin-induced myopathy and its underlying mecha-
nism require further investigation. We could not exclude the
involvement of risk factors other than the level of lactone
metabolite in atorvastatin-induced myotoxicity. Other factors
including alcohol consumption, diabetes or muscle inflam-
mationmay increase the risk of muscle injury in patients [20].4. Conclusion
In this report, a HPLC method was established with the use of
b-naphthoflavone as an internal standard for the quantitative
determination of serum atorvastatin in lipid-controlling pa-
tients. Although this method is time-consuming, the clear
separation and low cost make this method applicable for the
quantitative determination of high serum concentrations in
patients with potential myalgia adverse effect. The results of
our study showed that the serum concentrations in lipid-
controlling patients with myalgia were not significantly
higher than those in patients without myalgia.
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